Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

Figure 3

Proliferative capacity and apoptotic cells were observed in all treated groups. A: The effects of BM-06 plus sorafenib group were the most significant. A: Effect of 4 dsRNAs on proliferation of HepG2.2.15 cells. Growth curve of HepG2.2.15 cells was shown for each group. The proliferation was assayed in triplicates at 24 h, 48 h, and 72 h post-treatment using CCK-8 kits. (*, P< 0.05 vs control group;#, P< 0.05 vs BM-06 + sorafenib group) B: Apoptotic rates were measured in the treated HepG2.2.15 cells using a FACS analysis after Annexin-V-PI staining. Percentages of apoptotic cells included both early- and late-stage apoptosis (AV+/PI- and AV+/PI+). Increased rates of apoptosis in the treated groups were calculated relative to the PBS control. C: Apoptotic cells were observed in Hoechst nuclear staining (X200). D: Migrating cells were observed in a Transwell chambers assay (X100).

Back to article page